MedTrace Logo

Stem Cells Treatment for Bilateral Limbic Associated Keratopathy (HULPOFT)

NCT01808378 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-03-11

No results posted yet for this study

Summary

Evaluate the use of the autologous ASC for the treatment of bilateral limbic associated keratopathy

Conditions

  • Keratopathy

Interventions

DRUG

Expanded adipose-derived stem cells

Local injection of autologousadipose derived stem cells

Sponsors & Collaborators

  • Instituto de Investigación Hospital Universitario La Paz

    lead OTHER

Principal Investigators

  • Ana Boto de los Bueis, MD · Hospital Universitario La Paz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01808378 on ClinicalTrials.gov